Coronavirus neutralizing humanized antibodies and uses thereof
| DWPI Title: New isolated or purified single-domain antibody comprises variable domain comprising complementarity determining regions comprising specific polypeptide sequences, where variable domain binds to spike protein or receptor-binding domain of coronavirus, for use in treating viral infection |
| Abstract: The present disclosure relates to an isolated or purified antibody, or a fragment thereof, having a binding domain that binds to a coronavirus (e.g., SARS-COV-2) or a portion thereof. In other embodiments, the antibody includes a binding domain that competes with binding to angiotensin converting enzyme 2 (ACE2) or a portion thereof. Methods of using such antibodies are also described herein, such as methods of treating or delaying the progression of a disease associated with a coronavirus. |
| Use: Isolated or purified single-domain antibody for use in treating or prophylactically treating a viral infection, such as an infection from a coronavirus, and where the coronavirus is severe acute respiratory syndrome coronavirus 2 (claimed).No biological data given. |
| Advantage: The isolated or purified antibody or fragment binds to SARS-COV-2 or a portion (e.g., the spike protein or receptor-binding domain (RBD) of the spike protein). The complementarity determining regions (CDRs) that provide enhanced efficacy, as determined by reducing infectivity of a coronavirus and/or exhibiting binding to the coronavirus are identified, where such CDRs are provided in an antibody having any useful format, such as a nanobody or other forms. |
| Novelty: Isolated or purified single-domain antibody is new, where the isolated or purified single-domain antibody comprises a variable domain comprising a first complementarity determining region comprising polypeptide sequences of 7, 7, 7, 7 amino acids (SEQ ID Nos: 40, 41, 42, 43), given in the specification, a second complementarity determining region comprising polypeptide sequences of 8, 8, 8, 8 amino acids (SEQ ID Nos: 74, 75, 76, 77), given in the specification, and a third complementarity determining region comprising polypeptide sequences of 12, 12, 15, 12 amino acids (SEQ ID Nos: 108, 109, 110, 111), given in the specification, where the variable domain binds to a spike protein of a coronavirus or a receptor-binding domain of a coronavirus, and where the coronavirus is severe acute respiratory syndrome coronavirus 2. |
| Filed: 3/4/2021 |
| Application Number: US17191764A |
| Tech ID: SD 15639.0 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |